Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia

Blood

Volumn 118, Issue 12, 2011, Pages 3359-3366

  Maugeri, Norma ^a   Malato, Simona ^a   Femia, Eti A ^b   Pugliano, Mariateresa ^b   Campana, Lara ^a   Lunghi, Francesca ^a   Rovere Querini, Patrizia ^a   Lussana, Federico ^b   Podda, GianMarco ^b   Cattaneo, Marco ^b   Ciceri, Fabio ^a   Manfredi, Angelo A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYUREA; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOSIS;

EID: 80053206705     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337337     Document Type: Article

References (38)

1. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost. 2006;4(12):2593-2598. (Pubitemid 44741554)
2. Maugeri N, Baldini M, Rovere-Querini P, Maseri A, Sabbadini MG, Manfredi AA. Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity. 2009;42(4):386-388.
3. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38(4):1002-1006. (Pubitemid 32912702)
4. Jensen MK, De Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143-151. (Pubitemid 32324580)
5. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-530. (Pubitemid 40592168)
6. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104(13):1533-1537. (Pubitemid 32917347)
7. Maugeri N, Rovere-Querini P, Evangelista V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrin-dependent cell clearance program. Blood. 2009;113(21):5254- 5265.
8. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30(12):2357-2361.
9. Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol. 2010;17(1):3-8.
10. Rand ML, Wang H, Bang KW, Poon KS, Packham MA, Freedman J. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost. 2004;2(4):651-659. (Pubitemid 40185691)
11. Ruggeri ZM. Platelet adhesion under flow. Microcirculation. 2009;16(1):58-83.
12. Camera M, Frigerio M, Toschi V, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol. 2003;23(9):1690-1696. (Pubitemid 37108218)
13. Camera M, Brambilla M, Toschi V, Tremoli E. Tissue factor expression on platelets is a dynamic event. Blood. 2010;116(23):5076-5077.
14. Mezzano D, Matus V, Saez CG, Pereira J, Panes O. Tissue factor storage, synthesis and function in normal and activated human platelets. Thromb Res. 2008;122(suppl 1):S31-S36.
15. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood. 2007; 109(12):5242-5250. (Pubitemid 46890544)
16. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol. 2009;147(4): 415-430.
17. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood. 2010;116(12): 2011-2018.
18. Wood JP, Silveira JR, Maille NM, Haynes LM, Tracy PB. Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity. Blood. 2011;117(5):1710-1718.
19. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2): 169-175.
20. Cervantes F, Arellano-Rodrigo E, Alvarez-Larran A. Blood cell activation in myeloproliferative neoplasms. Haematologica. 2009;94(11):1484-1488.
21. Cortelazzo S, Viero P, Barbui T. Platelet activation in myeloproliferative disorders. Thromb Haemost. 1981;45(3):211-213. (Pubitemid 11081031)
22. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108(2-3): 139-145. (Pubitemid 36187452)
23. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-2168. (Pubitemid 41291734)
24. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464): 1054-1061. (Pubitemid 40386783)
25. Maugeri N, Santarelli MT, Lazzari MA. Circulating platelet/ polymorphonuclear leukocyte mixed-cell aggregates in patients with mechanical heart valve replacement. Am J Hematol. 2000;65(2):93-98.
26. Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost. 2006;4(6):1323-1330.
27. Ferri LA, Maugeri N, Rovere-Querini P, et al. Antiinflammatory action of apoptotic cells in patients with acute coronary syndromes. Atherosclerosis. 2009;205(2):391-395.
28. Evangelista V, Pamuklar Z, Piccoli A, et al. Src family kinases mediate neutrophil adhesion to adherent platelets. Blood. 2007;109(6):2461-2469. (Pubitemid 46425889)
29. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19(3 suppl 9):1-10.
30. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol. 2006;13(1):40-44.
31. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562-564.
32. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112(1):87-97. (Pubitemid 36106421)
33. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9(1):61-67. (Pubitemid 36098261)
34. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009; 124(4):409-417.
35. Carobbio A, Finazzi G, Antonioli E, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9): 1016-1021.
36. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
37. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313-320. (Pubitemid 46878103)
38. Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7):1051-1055.